跳至主要内容
临床试验/NL-OMON43478
NL-OMON43478已完成不适用

Assessing cholinergic innervation in Parkinson*s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol - Cholinergic PET imaging in Parkinson*s disease

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Control Subjects:
  • - Age between 45 - 65 years
  • - Willingness to cooperate and sign written informed consent
  • - No prior history of neurologic or psychiatric illness
  • - Able and fit enough to participate in this study;Patient Group:
  • - Diagnosis Parkinson*s disease
  • - Disease duration between 3 and 10 years.
  • - Age between 45 - 65 years
  • - Willingness to cooperate and sign written informed consent

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • - The refusal to be informed about an unforeseen clinical finding
  • - Pregnant women, breast feeding
  • - Exhibition to a radiation dose for other reasons (e.g. participation in other research trial), exceeding the maximum annual dose.
  • - Anticoagulant medication, antiplatelet agents used in the 5d before the imaging visit
  • - Contra-indication for MRI-scanning (metal parts in the body)
  • - Other neurological conditions, more specifically neurodegenerative disorders and brain lesions.
  • - Treatment with deep brain stimulation

研究者

相似试验